Helicobacter pylori(HP) eradication: a randomized prospective study of triple therapy with or without Eupatilin

H.pylori eradication: a randomized prospective study of triple therapy with or without Eupatilin

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

CRIS

Registry ID

KCT0001528

Enrollment

300

Registered

2015-06-18

Start date

2010-12-22

Completion date

Unknown

Last updated

2019-03-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Drug : (1) Group 1: Hp eradication (lansopraxole 60 mg, amoxicillin 2000 mg, clarithromycin 1000 mg) for 1 week (2)Group 2: Hp eradication (lansopraxole 60 mg, amoxicillin 2000 mg, clarithromycin 1000

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Patients receiving HP eradication therapy for treatment of peptic ulcer, gastric cancer and gastritis. 2. Patients agreed to the study by written consents.

Exclusion criteria

Exclusion criteria: 1. Previous HP eradication history 2. Allergic reactions to the drug used in this study 3. Pregnancy or severe comorbidity 4. Recieved proton pump inhibitors within 4 weeks before the start of study 5. Recieved H2 recepter antagonists or antibiotics within 4 weeks before the start of study

Design outcomes

Primary

Measure	Time frame
the Eradication of H. pylori (helicobacter pylori)	—

Secondary

Measure	Time frame
Adverse events after Hp eradication therapy	—

Countries

Korea, Republic of

Contacts

Public ContactChangHwan CHOI

Chung-Ang Univerisity Hospital

Outcome results